Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optive UD is a preservative-free artificial tear formulation developed by Allergan (now AbbVie) for the symptomatic relief of dry eye and ocular surface irritation. The formulation contains carboxymethylcellulose sodium (0.5%) and glycerin (0.9%) as active lubricating ingredients. It functions as a mucomimetic and lubricant, increasing tear film stability and providing a protective layer over the corneal and conjunctival epithelium. In clinical research, specifically a Phase 2/3 study (NCT01799863) conducted by Fundação Altino Ventura, Optive UD was utilized as a control arm to evaluate the efficacy of lubricating drops in managing the signs and symptoms of acute viral conjunctivitis compared to a ketorolac-based combination therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Optive UD.